Who Owns Piramal Consumer Healthcare?

Piramal Consumer Healthcare operates within Piramal Pharma Limited's sustainability framework, which is built on four pillars: business resilience, quality excellence, responsible operations, and stakeholder centricity. The company has established over 50 time-bound sustainability targets.

In 2025, Piramal Pharma achieved a notable score increase on the S&P Global Corporate Sustainability Assessment (CSA). The CSA is one of the world's most respected sustainability benchmarking frameworks, and the score increase reflected progress in implementing sustainable business practices across all divisions.

Piramal Consumer Healthcare maintains quality standards across its product portfolio, which includes Littles, Lacto Calamine, i-pill, and Tetmosol. The division's quality management systems ensure product safety, efficacy, and compliance with regulatory requirements set by India's Central Drugs Standard Control Organization.

Through the Piramal Foundation, the company executes CSR programs focused on healthcare access, education, and community development. The Piramal Foundation operates initiatives in rural healthcare, education, and women's empowerment across India. Piramal Consumer Healthcare's mission to provide affordable healthcare products aligns with these CSR objectives.

The division reaches 70 million consumers per month and focuses on building trusted relationships through transparent communication and ethical marketing. The company's products are priced in the mid-range segment, making them accessible to a broad cross-section of Indian consumers.

Piramal Pharma has established environmental targets including energy efficiency improvements, water conservation measures, and waste reduction programs. Piramal Consumer Healthcare's manufacturing operations in India are subject to these corporate-wide environmental standards.

Piramal Consumer Healthcare has been recognized for its growth and brand building in the Indian consumer healthcare sector. The division is ranked among the top OTC players in India, a significant achievement for a division established in 2010.

Most of the division's products rank either first or second in their respective market categories. Brands like Littles, Lacto Calamine, i-pill, and Tetmosol hold dominant positions in their segments. This market leadership reflects the division's ability to build and maintain consumer healthcare brands in a competitive market.

The division reaches approximately 70 million consumers per month across India, representing one of the largest consumer footprints in the Indian OTC healthcare market. This reach has been recognized as evidence of effective brand building and distribution strategy.

Piramal Consumer Healthcare has been acknowledged as one of the fastest-growing businesses within Piramal Pharma Limited. The division's growth trajectory has been cited by industry analysts as evidence of effective market positioning and product innovation.

In 2026, the division's selection of OMD India for its integrated media mandate was recognized as a strategic move to enhance brand presence. The partnership was reported by Storyboard18 and the Economic Times, reflecting industry confidence in the division's growth potential.

Piramal Consumer Healthcare has not experienced any major product recalls as of August 2026. However, its parent company Piramal Pharma Limited has faced regulatory scrutiny at manufacturing facilities that supply the broader pharmaceutical business.

FDA Form 483 at Maharashtra Facility (February 2025): The U.S. FDA issued a Form 483 to Piramal Pharma's production facility in Maharashtra, India, detailing six observations related to quality control deficiencies. The inspection was conducted from February 11 to 17, 2025. The FDA found that Piramal's quality control unit procedures were "not in writing and fully followed." Inspectors discovered a leak from manufacturing equipment that resulted in liquid on the floor, with no operator or supervisor present and no documentation of operator activity. The FDA also noted that Piramal's investigations into API batch deviations lacked adequate follow-up, with four manufacturing deviations reported in March 2024 but no documented quality risk assessment produced.

Previous FDA Form 483 at Michigan Facility (February 2024): The 2025 FDA action followed a similar Form 483 issued in February 2024 at Piramal's manufacturing plant in Michigan, USA. The repeated regulatory scrutiny across different facilities indicates quality control challenges within Piramal Pharma's global manufacturing network.

Impact on Consumer Healthcare Division: The FDA actions primarily targeted Piramal Pharma's API manufacturing operations, not the consumer healthcare division's OTC products. However, the regulatory scrutiny affects the entire company's reputation. Consumers and healthcare professionals may question whether quality control issues extend to OTC products manufactured at related facilities.

Piramal Pharma confirmed it was preparing detailed responses to address all FDA observations within regulatory timelines. The company has not disclosed the full content of its corrective and preventive action plans.